Can a tiny metal plug fix painful ankle defects?

NCT ID NCT06522139

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether a small metal implant, called the Episealer Talus, can relieve pain and improve function in people with a specific type of ankle cartilage damage. The study will enroll 20 adults aged 18 to 65 who have a focal defect on the talus bone and have not improved with conservative care. Participants will receive the implant and be followed for 60 months to measure changes in pain and symptoms, and to check how long the implant lasts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Implantation of the Episealer Talus implant, a small metal device placed into the damaged area of the ankle bone.
What this could lead to
If it works, this could offer a durable option for people with ankle cartilage damage who have not improved with other treatments, potentially delaying or avoiding more invasive surgery.
What could go wrong
This is a small, early-stage study with only 20 participants, and results may not apply to everyone. The implant could loosen, cause pain, or require revision surgery, as seen in some earlier reports.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Oct 2021

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Osteochondral lesion (both primary and secondary lesions) ⌀ 10-15 mm on the medial or lateral talar dome * age between 18 and 65 years * BMI \< 35 * patients who have given their willingness to reach the Institute for checkups. * patients previously treated with conservative therapies, which proved unsuccessful Exclusion Criteria: * non-focal defect * on-going infection in the ankle joint * inflammatory arthritis or radiographic osteoarthritis in the ankle joint (=no joint space narrowing) Osteophytes without joint space narrowing (=Gr1 (van Dijk classification)) is not a contra indication. * sensitivity to cobalt-chrome alloys and titanium materials * inadequate bone stock where the Episealer is to be inserted * existing prosthesis in the area of treatment or opposing surface * osteochondral lesion on opposing tibial surface * pain of unknown etiology * demineralised bone * instability. Instability is defined as recurrent giving way with or without laxity * severe malalignment in the ankle joint \>5 degrees malalignment as compared to the contralateral ankle joint, as measured on the standing X-Ray * Ipsilateral symptomatic foot, knee or hip disease which affects the mobility of the patient * other diseases or medication that may affect the bone anchoring of the Episealer * uncooperative patient that is not willing to follow instructions * muscular insufficiency * vascular insufficiency * medical, hormonal, hematological, immunological or metabolic illnesses * Smoking * Pregnancy * Diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteochondral defect are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • IRCCS Istituto Ortopedico Rizzoli

    Bologna, 40136, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.